Abstract
Patients with hormone escaped advanced progressive prostate cancer were randomized either to receive either high-dose Estramustine phosphate orally or Mitomycin C by i.v. injection every 6 weeks until signs of progression or death supervened. Patients on both arms progressed rapidly, with a median time to progression of 5 months and a median length of survival of only 10 months. Toxicity was very considerable in both arms.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Estramustine / adverse effects
-
Estramustine / therapeutic use*
-
Europe / epidemiology
-
Humans
-
Male
-
Mitomycin
-
Mitomycins / adverse effects
-
Mitomycins / therapeutic use*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / epidemiology
-
Prostatic Neoplasms / secondary
-
Risk Factors
-
Survival Analysis
Substances
-
Mitomycins
-
Estramustine
-
Mitomycin